Amgen (AMGN) Says Phase 3 A.R.R.O.W. Study of Once-Weekly KYPROLIS Regimen Meet Primary Endpoint of Progression-Free Survival In R/R Multiple Myeloma Patients
October 23, 2017 4:02 PM
Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
_58cbc46cd3c33.jpg)
